Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 11524494.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors evaluated whether glatiramer acetate (GA) modifies the severity of tissue damage in 1,722 new lesions from 239 patients with MS enrolled in a placebo-controlled trial monitored with monthly cerebral MRI. The percentage of new lesions that evolved into "black holes" was lower in GA-treated than in placebo patients on scans at 7 (18.9 and 26.3%; p = 0.04) and 8 (15.6 and 31.4%; p = 0.002) months after lesion appearance. GA has a favorable effect on tissue disruption in MS lesions once they are formed.
Medical subject headings
- Brain
- Immunosuppressive Agents
- Multiple Sclerosis
- Peptides